About us About us
About us

Based at BioCity, Nottingham, UK, Haemostatix Ltd was co-founded in 2003 by Sarah Middleton and Professor Alison Goodall as a spin-out from the University of Leicester. The Company was established to commercialise a new technology platform based upon a specific peptide sequence that binds to fibrinogen - a protein essential to the formation of clots. The technology was first applied to the development of a systemic platelet substitute, but in 2010 the Company re-focused on a topical coagulant, led by a new CEO, Dr Ben Nichols and Chairman Dr Robert Burns.

The Company has been backed by institutional investment funds managed by Albion Ventures, Catapult Venture Managers, NESTA, Esperante and Braveheart/Lachesis. The Company has also received convertible loans from the Wellcome Trust to support development of its lead candidate, PeproStat. On the 23rd May 2016 Haemostatix was acquired by Ergomed plc (LSE AIM ERGO), a profitable pharmaceutical services business. Ergomed engages in managed risk product development and co-development, alongside providing revenue generating services.

Key facts about Haemostatix
  • Novel peptide-based platform technology protected by 9 patent families
  • Pipeline of topical haemostats, with further applications in tissue repair and regenerative medicine
  • Lead product PeproStat™ Liquid is a topical haemostat for the treatment of bleeding during surgery
  • PeproStat™ Liquid has successfully completed a clinical trial in liver surgery patients at four UK hospitals